Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18761525 | 1.00 | KDM1A (0.43) | KDM1AHTR2ASIGMAR1OPRM1OPRD1 | |
| SCHEMBL30327609 | 1.00 | KDM1A (0.43) | KDM1AHTR2ASIGMAR1OPRM1OPRD1 | |
| SCHEMBL2805938 | 1.00 | KDM1A (0.43) | KDM1AHTR2ASIGMAR1OPRM1OPRD1 | |
| SCHEMBL4199129 | 1.00 | KDM1A (0.43) | KDM1AHTR2ASIGMAR1OPRM1OPRD1 | |
| SCHEMBL191836 | 1.00 | KDM1A (0.43) | KDM1AHTR2ASIGMAR1OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL25254960 | 0.98 | KDM1A (0.46) | KDM1AHTR2ASIGMAR1OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL2807464 | 0.98 | KDM1A (0.46) | KDM1AHTR2ASIGMAR1OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL2809120 | 0.98 | KDM1A (0.46) | KDM1AHTR2ASIGMAR1OPRM1OPRD1 | |
| SCHEMBL22457171 | 0.84 | KDM1A (0.46) | KDM1AHTR2ASIGMAR1IDO1GRIN2D | |
| SCHEMBL783972 | 0.81 | IDO1 (0.49) | SIGMAR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023102747-A1 | ANTIMALARIAL AGENTS | MERCK SHARP & DOHME LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| US-10442793-B2 | Oxa spiro derivative, preparation method therefor, and applications thereof in medicines | JIANGSU HENGRUI MEDICINE CO., LTD (CN) | 2019-10-15 | — | — | US | disclosed |
| US-20190255052-A1 | Inhibitors of E1 Activating Enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| WO-2017063509-A1 | OXA SPIRO DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN MEDICINES | 江苏恒瑞医药股份有限公司 | 2017-04-20 | — | — | WO | disclosed |
| EP-2402334-B1 | Inhibitors of E1 Activating Enzymes | MILLENNIUM PHARM INC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20130289037-A1 | INHIBITORS OF E1 ACTIVTING ENZYMES | MILLENNIUM PHARM INC (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130165457-A9 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120258977-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| EP-1989206-B1 | INHIBITORS OF E1 ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2012-07-04 | — | — | EP | disclosed |
| US-8207177-B2 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2402334-A1 | Inhibitors of E1 Activating Enzymes | Millennium Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2011039344-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN TYROSINE KINASE 2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-07 | — | — | WO | disclosed |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442793-B2 | Oxa spiro derivative, preparation method therefor, and applications thereof in medicines | OPRL1, OPRD1, OPRK1 | KDM1A 4178/4885HTR2A 898/4885SIGMAR1 26/4885 |
| US-20120258977-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | KDM1A 513/4885HTR2A 4708/4885SIGMAR1 4592/4885 |
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | KDM1A 513/4885HTR2A 4708/4885SIGMAR1 4592/4885 |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | KDM1A 513/4885HTR2A 4708/4885SIGMAR1 4592/4885 |
| US-20190255052-A1 | Inhibitors of E1 Activating Enzymes | ECE1, RNASE1, RCE1 | KDM1A 513/4885HTR2A 4708/4885SIGMAR1 4592/4885 |
| US-20130165457-A9 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | KDM1A 513/4885HTR2A 4708/4885SIGMAR1 4592/4885 |
| US-20130289037-A1 | INHIBITORS OF E1 ACTIVTING ENZYMES | RNASE1, ECE1, CES1 | KDM1A 324/4885HTR2A 4766/4885SIGMAR1 4656/4885 |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | KDM1A 513/4885HTR2A 4708/4885SIGMAR1 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.